Nikolaus Krall
Nikolaus Krall
CeMM (Center for Molecular Medicine of the Austrian Academy of Sciences)
Verified email at - Homepage
Cited by
Cited by
Site-selective protein-modification chemistry for basic biology and drug development
N Krall, FP Da Cruz, O Boutureira, GJL Bernardes
Nature chemistry 8 (2), 103-113, 2016
A small‐molecule drug conjugate for the treatment of carbonic anhydrase IX expressing tumors
N Krall, F Pretto, W Decurtins, GJL Bernardes, CT Supuran, D Neri
Angewandte Chemie International Edition 53 (16), 4231-4235, 2014
Small targeted cytotoxics: current state and promises from DNA‐encoded chemical libraries
N Krall, J Scheuermann, D Neri
Angewandte Chemie International Edition 52 (5), 1384-1402, 2013
Dual-display of small molecules enables the discovery of ligand pairs and facilitates affinity maturation
M Wichert, N Krall, W Decurtins, RM Franzini, F Pretto, P Schneider, ...
Nature chemistry 7 (3), 241-249, 2015
Curative properties of noninternalizing antibody–drug conjugates based on maytansinoids
E Perrino, M Steiner, N Krall, GJL Bernardes, F Pretto, G Casi, D Neri
Cancer research 74 (9), 2569-2578, 2014
A bivalent small molecule-drug conjugate directed against carbonic anhydrase IX can elicit complete tumour regression in mice
N Krall, F Pretto, D Neri
Chemical Science 5 (9), 3640-3644, 2014
Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study
B Snijder, GI Vladimer, N Krall, K Miura, AS Schmolke, C Kornauth, ...
The Lancet Haematology 4 (12), e595-e606, 2017
Receiver-autonomous vertical integrity monitoring
RC Hilb
US Patent 6,711,478, 2004
A 99mTc-labeled ligand of carbonic anhydrase IX selectively targets renal cell carcinoma in vivo
N Krall, F Pretto, M Mattarella, C Müller, D Neri
Journal of Nuclear Medicine 57 (6), 943-949, 2016
A comprehensive surface proteome analysis of myeloid leukemia cell lines for therapeutic antibody development
V Strassberger, KL Gutbrodt, N Krall, C Roesli, H Takizawa, MG Manz, ...
Journal of proteomics 99, 138-151, 2014
Tumor-Targeting Antibody–Anticalin Fusion Proteins for in Vivo Pretargeting Applications
M Steiner, K Gutbrodt, N Krall, D Neri
Bioconjugate chemistry 24 (2), 234-241, 2013
Targeting carbonic anhydrase IX with small organic ligands
M Wichert, N Krall
Current opinion in chemical biology 26, 48-54, 2015
Entwicklung zielgerichteter niedermolekularer zytotoxischer Wirkstoffverbindungen mit DNA‐codierten chemischen Bibliotheken
N Krall, J Scheuermann, D Neri
Angewandte Chemie 125 (5), 1424-1443, 2013
Global survey of the immunomodulatory potential of common drugs
GI Vladimer, B Snijder, N Krall, JW Bigenzahn, KVM Huber, CH Lardeau, ...
Nature chemical biology 13 (6), 681, 2017
Combined chemosensitivity and chromatin profiling prioritizes drug combinations in CLL
C Schmidl, GI Vladimer, AF Rendeiro, S Schnabl, T Krausgruber, ...
Nature chemical biology 15 (3), 232-240, 2019
Ein niedermolekulares Ligand‐Wirkstoff‐Konjugat zur Behandlung von Carboanhydrase IX exprimierenden Tumoren
N Krall, F Pretto, W Decurtins, GJL Bernardes, CT Supuran, D Neri
Angewandte Chemie 126 (16), 4315-4320, 2014
(In) organic anions as carbonic anhydrase inhibitors
N Krall, F Pretto, W Decurtins, SU Rehman, ZH Chohan, F Gulnaz, ...
Angew Chem Int Ed Engl 53, 4231-5, 2014
Small molecule drug conjugates
N Krall, W Decurtins, D Neri, J Scheuermann, M Wichert
ES Patent App. 15,702,001 T, 2019
Functional Precision Medicine in AML: Technical Performance Evaluation for in Vitro Diagnostics Using High-Throughput Image-Based Screening of Primary …
N Krall, N Meszaros, K Lind, B Vilagos, H Sill, GI Vladimer
Blood, The Journal of the American Society of Hematology 134 (Supplement_1 …, 2019
Patient-derived model systems and the development of next-generation anticancer therapeutics
N Krall, G Superti-Furga, GI Vladimer
Current Opinion in Chemical Biology 56, 72-78, 2020
The system can't perform the operation now. Try again later.
Articles 1–20